Home  »  Market   »  Analyzing Emergent BioSolutions Inc. (EBS) From To...

Analyzing Emergent BioSolutions Inc. (EBS) From Top to Bottom,

On Tuesday, shares of Emergent BioSolutions Inc. (NYSE:EBS) marked $96.26 per share versus a previous $111.47 closing price. With having a -13.64% loss, an insight into the fundamental values of Emergent BioSolutions Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. EBS showed a rise of 78.42% within its YTD performance, with highs and lows between $46.37 – $137.61 during the period of 52 weeks, compared to the simple moving average of 18.89% in the period of the last 200 days.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


JP Morgan equity researchers changed the status of Emergent BioSolutions Inc. (NYSE: EBS) shares to a “Neutral” rating in the report published on September 14th, 2020. Other analysts, including Chardan Capital Markets, also published their reports on EBS shares. Chardan Capital Markets repeated the rating from the previous report, marking EBS under “Buy” rating, in the report published on July 31st, 2020. Additionally, EBS shares got another “Buy” rating from Guggenheim. On the other hand, Goldman Upgrade the “Buy” rating for EBS shares, as published in the report on November 2nd, 2018. Chardan Capital Markets seems to be going bullish on the price of EBS shares, based on the price prediction for EBS, indicating that the shares will jump from $53 to $57, giving the shares “Buy” rating based on their report from August 3rd, 2018. Another “Buy” rating came from Argus, providing a prediction for $57 price target according to the report published in June 13th, 2018.

[bold-text]Emergent BioSolutions Inc. (EBS) Analysis[/bold-text]

The present dividend yield for EBS owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. However, in order for the company to be able to pay its dividends, just like it is the case with Emergent BioSolutions Inc., the company needs to provide a healthy cash flow, currently at the value of 26.48. In addition, the growth of sales from quarter to quarter is recording 62.30%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of Emergent BioSolutions Inc. (EBS) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of 15.50% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 1.90 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while EBS is currently recording an average of 869.60K in volumes. The volatility of the stock on monthly basis is set at 4.35%, while the weekly volatility levels are marked at 5.55%with -13.52% of loss in the last seven days. Additionally, long-term investors are predicting the target price of $112.29, indicating growth from the present price of $96.26, which can represent yet another valuable research and analysis points that can help you decide whether to invest in EBS or pass.

[bold-text]What to Look for When Analyzing Emergent BioSolutions Inc. Shares?[/bold-text]

Emergent BioSolutions Inc. (EBS) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare EBS shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of 29.97 for Emergent BioSolutions Inc., while the value 11.67 can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value 3.21 is supported by the yearly EPS growth of -8.50%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 2.90%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 87.40% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

[bold-text]Are Institutional Investors Increasing Stakes in EBS Shares?[/bold-text]

It appears that more than several institutional investors and hedge funds decided to increase stakes in EBS in the recent period. That is how BlackRock Fund Advisors now has an increase position in EBS by 1.92% in the first quarter, owning 6.26 million shares of EBS stocks, with the value of $646.87 million after the purchase of an additional 117,795 shares during the last quarter. In the meanwhile, The Vanguard Group, Inc. also increased their stake in EBS shares changed 0.06% in the first quarter, which means that the company now owns 4.61 million shares of company, all valued at $476.37 million after the acquisition of additional 2,957 shares during the last quarter.

Neuberger Berman Investment Advis acquired a new position in Emergent BioSolutions Inc. during the first quarter, with the value of $308.8 million, and SSgA Funds Management, Inc. increased their stake in the company’s shares by 2.20% in the first quarter, now owning 47,929 shares valued at $229.67 million after the acquisition of the additional 2.22 million shares during the last quarter. At the present, 87.40% of EBS shares are in the ownership of institutional investors.

Leave a Comment

Your email address will not be published.

Related Posts




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam